Evidence map›Paper›PMID 40115544›Full record

ArticleCase reports in oncology

Thrombocytopenia in an EGFR 19 Exon-Deficient Bilateral Diffuse LUAD with ARDS Treated with ECMO and Osimertinib: A Case Report.

Donghai Liang, Fei Zhou, Chen Xu, Lili Zou, Tao Jiang, Haijun Lu, Chunliu Meng

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Case reports in oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Donghai LiangDepartment of Radiation Oncology, The Affiliated Hospital of Qingdao University, Qingdao, China.
Fei ZhouDepartment of Radiation Oncology, The Affiliated Hospital of Qingdao University, Qingdao, China.
Chen XuDepartment of Oncology, Second Affiliated Hospital of Qingdao University, Qingdao, China.
Lili ZouDepartment of Oncology, Qingdao West Coast New Area People's Hospital, Qingdao, China.
Tao JiangDepartment of Radiation Oncology, The Affiliated Hospital of Qingdao University, Qingdao, China.
Haijun LuDepartment of Radiation Oncology, The Affiliated Hospital of Qingdao University, Qingdao, China.
Chunliu MengDepartment of Radiation Oncology, The Affiliated Hospital of Qingdao University, Qingdao, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: EGFR-sensitive mutations bilateral diffuse lung adenocarcinoma (LUAD) complicated with acute respiratory distress syndrome (ARDS) is relatively rare. It is important to consider whether EGFR-TKI can be simultaneously received when treating with extracorporeal membrane oxygenation (ECMO) and anti-infective therapy in these patients, and what adverse events should be noted? Case Presentation: We report a case of EGFR 19 exon-deficient bilateral diffuse LUAD complicated with ARDS. When treated with ECMO and anti-infective therapy, the patient received oral osimertinib anti-tumor therapy simultaneously. The tumor receded, but eventually irreversible thrombocytopenia developed. Conclusion: For patients with severe lung cancer, anti-tumor efficacy and adverse events should be closely observed during anti-tumor therapy.

Indexed as

Acute respiratory distress syndromeBilateral diffuse lung adenocarcinomaExtracorporeal membrane oxygenationOsimertinibThrombocytopenia

Identifiers

PMID40115544
PMCPMC11925480

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.